Modifiers | Histone modification | Targets | Effects on fate of BM-MSC (in vitro) | Effects on bone (in vivo) | References |
---|---|---|---|---|---|
Methylases | Â | Â | Â | Â | Â |
ASH1L | H3K4me3 | Osx, Runx2, Hoxa10, Sox9, Creb | Promotes osteogenesis and chondrogenesis, while inhibiting adipogenesis | Not evaluated | [70] |
EZH2 (KMT6A) | H3K27me3 | Osteoblastic genes (RUNX2, TCF7, BGLAP, Wnt, Bmp2), senescence-associated genes (p14Arf, p16Ink4a, p21Cip1), antioxidant Foxo1 | Inhibits osteogenesis, while promoting adipogenesis, restraining senescence, accumulating oxidative damage | Inconsistent conclusion | |
NSD1 (SETD2, SET2, KMT3A) | H3K36me3 | Lbp | Promotes osteogenesis while inhibiting adipogenesis | Promotes bone mass increase | [29] |
NSD2 (MMSET) | H3K36me2 H3K27me3 | Runx2, Bglap | Promotes osteogenesis while inhibiting senescence | Not evaluated | [21] |
SETD7 (SET7, SET9, SET7/9, KMT7) | H3K4me3 | Not evaluated | Promotes osteogenesis | Not evaluated | [72] |
PRMT3 | H4R3me2a | miR-3648 | Promotes osteogenesis | Promotes bone regeneration and bone mass increase | [103] |
PRMT4 (CARM1) | H3R17me2 | OCT4, SOX2, NANOG, DDR2 | Promotes pluripotency while inhibiting senescence | Not evaluated | |
Demethylases | Â | Â | Â | Â | Â |
LSD1 (KDM1A) | H3K9me2 | Pparγ2 | Promotes adipogenesis | Not evaluated | [64] |
LSD1 | H3K4me2 | Runx2, Bglap, Wnt7b, Bmp2 | Inhibits osteogenesis | Promotes bone loss | |
KDM3A (JMJD1A, JHDM2A) | H3K9me2 H3K9me3 | Ncapd2, Ncapg2 | Inhibits DNA damage and senescence | Inhibits bone loss | [68] |
KDM4A (JMJD2A, JHDM3A, JMJD2) | H3K9me3 | Runx2, Osx, Bglap | Promotes osteogenesis | Not evaluated | [66] |
KDM4A | H3K9me3 | Sfrp4, C/ebpα | Promotes adipogenesis while inhibiting canonical Wnt signaling | Not evaluated | [65] |
KDM4B (JMJD2B, JHDM3B) | H3K9me3 | Runx2, Dlx5, Ccnd1, Hif1α, Mef2a | Promotes osteogenesis while inhibiting adipogenesis | Inhibits age-related bone loss | |
KDM4C (GASC1, JMJD2C, JHDM3C) | H3K9me2 H3K9me3 | Ncapd2, Ncapg2 | Inhibits DNA damage and senescence | Inhibits bone loss | [68] |
KDM5A (JARID1A, RBP2) | H3K4me3 | Runx2 | Inhibits osteogenesis | Promotes bone loss | [75] |
KDM5B (JARID1B, PLU1) | H3K4me3 | Runx2 | Inhibits osteogenesis | Not evaluated | [76] |
KDM6A (UTX) | H3K27me3 | RUNX2, BGLAP | Promotes osteogenesis | Not evaluated | |
KDM6B (JMJD3) | H3K27me3 | Bmp2, Bmp4, Hoxc6-1, Runx2 | Promotes osteogenesis while inhibiting adipogenesis | Not evaluated | |
KDM7A (KIA1718, JHDM1D) | H3K9me2 H3K27me2 | C/ebpα Sfrp1 | Promotes adipogenesis while inhibiting osteogenesis | Not evaluated | [58] |
Other regulators | Â | Â | Â | Â | Â |
BMI1 | H2Aub H3K27me3 | p14Arf, p16Ink4a, Pax3 | Promotes hematopoiesis while inhibiting adipogenesis and senescence | Inhibits bone marrow adiposity | [62] |
α-KG | H3K9me3 H3K27me3 | Bmp2, Bmp4, Nanog | Promotes proliferation, migration and osteogenesis | Inhibits age-related bone loss and promotes bone defect healing | [20] |
NO66 | H3K4me3 H3K36me3 | Not evaluated | Inhibits osteogenesis | Inhibits endochondral and intramembranous bone formation | [81] |